Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss
Información
- DOI:
- https://doi.org/10.1002/14651858.CD012852Copiar DOI
- Base de datos:
-
- Cochrane Database of Systematic Reviews
- Versión publicada:
-
- 03 noviembre 2017see what's new
- Tipo:
-
- Intervention
- Etapa:
-
- Protocol
- Grupo Editorial Cochrane:
-
Grupo Cochrane de Embarazo y parto
- Copyright:
-
- Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Cifras del artículo
Altmetric:
Citado por:
Autores
Contributions of authors
LJJS and MCM wrote the first version of the protocol. SM critically revised the protocol. LJJS and SM are guarantors of the review.
Declarations of interest
Luuk JJ Scheres: is a PhD‐candidate of the CREW project (2013T083) funded by the Netherlands Heart Foundation
Mauritia C Marijnen: none known
Saskia Middeldorp has received a personal Innovation VIDI grant (paid to her institution) on Thrombophilia and Reproduction from the Netherlands Organisation for Scientific Research (NWO). She has carried out paid consultancy (paid to her institution, and not in relation to this review) for Daiichi Sankyo (as a member of the Writing Committee of the Hokusai VTE study (published in 2013)); Daiichi Sankyo, Bayer, and Janssen (local investigator for various treatment and prophylaxis studies in VTE patients). She has received payment (to her institution) for lectures on VTE treatment from Bayer, BMS/Pfizer, Boehringer Ingelheim, Daiichi Sankyo, Sanofi, and for developing educational presentations for Bayer, Aspen, Daiichi Sankyo, BMS/Pfizer). Saskia also has grants/grants for investigator‐initiated studies from Aspen, Daiichi Sankyo and Bayer, all paid to her institution.
Acknowledgements
LJJ Scheres is a PhD‐candidate of the CREW project (2013T083) supported by the Netherlands Heart Foundation. Saskia Middeldorp is supported by a VIDI grant from The Netherlands Organisation for Health Research and Development (016.126.364).
As part of the pre‐publication editorial process, this protocol has been commented on by three peers (an editor and two referees who are external to the editorial team), and the Group's Statistical Adviser.
This project was supported by the National Institute for Health Research, via Cochrane Infrastructure funding to Cochrane Pregnancy and Childbirth. The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the Systematic Reviews Programme, NIHR, NHS or the Department of Health.
Version history
| Published | Title | Stage | Authors | Version |
| 2020 May 02 | Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss | Review | Eva N Hamulyák, Luuk JJ Scheres, Mauritia C Marijnen, Mariëtte Goddijn, Saskia Middeldorp | |
| 2017 Nov 03 | Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss | Protocol | Luuk JJ Scheres, Mauritia C Marijnen, Saskia Middeldorp | |
